Flu (Influenza) and Pneumonia Immunization Vaccines
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Flu (Influenza) and Pneumonia Immunization Vaccines
Policy Number: PG0196 ADVANTAGE | ELITE | HMO
Last Review: 10/01/2021 INDIVIDUAL MARKETPLACE |
PROMEDICA MEDICARE
PLAN | PPO
GUIDELINES
This policy does not certify benefits or authorization of benefits, which is designated by each individual
policyholder terms, conditions, exclusions and limitations contract. It does not constitute a contract or
guarantee regarding coverage or reimbursement/payment. Self-Insured group specific policy will
supersede this general policy when group supplementary plan document or individual plan decision
directs otherwise.
Paramount applies coding edits to all medical claims through coding logic software to evaluate the
accuracy and adherence to accepted national standards.
This medical policy is solely for guiding medical necessity and explaining correct procedure reporting
used to assist in making coverage decisions and administering benefits.
SCOPE
X Professional
_ Facility
DESCRIPTION
The flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and lungs. It can
cause mild to severe illness, and at times can lead to death. Vaccination to prevent influenza is particularly
important for persons who are at increased risk for severe illness and complications from influenza and for
influenza-related outpatient, emergency department, or hospital visits. The best way to prevent the flu is by getting
a flu vaccine each year. Pneumonia vaccine is an infection of the lung, and can be caused by nearly any class of
organism known to cause human infections, bacteria, viruses, fungi and parasites.
Vaccines prevent disease in the people who receive them and protect those who are exposed to unvaccinated
individuals. Immunization, also known as vaccination, is a means of triggering acquired immunity against certain
infectious diseases. This is a specialized form of immunity that provides long-lasting protection against specific
antigens, such as certain diseases. Small doses of an antigen (such as dead or weakened live viruses) are given to
activate the body’s immune system. Persons who receive the vaccine will be immune only to those strains of the
virus from which the vaccine was prepared.
Vaccinations/immunizations are covered when recommended by the Centers for Disease Control and Prevention
(CDC) and the American Academy of Pediatrics (AAP) and when US Food and Drug Administration (FDA)
guidelines are met.
The Advisory Committee on Immunization Practices (ACIP) of the Centers of Disease Control and Prevention
(CDC) web site contains the most current information regarding the use of vaccines and immunizations in the
United States, including both recommendations/schedules and precautions. ACIP Recommendations:
http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/index.html
POLICY
Flu and Pneumonia Immunization Vaccines do not require prior authorization.
Vaccination Products Pending FDA Approval are non-covered, including but not limited to 90666,
90667, & 90668.
PG0196 – 10/01/2021Code 90664 (pandemic vaccine) is non-covered for HMO, PPO, Individual Marketplace, &
Elite/ProMedica Medicare Plan.
HMO, PPO, Individual Marketplace members must receive the vaccine from participating
providers.
Advantage and Elite/ProMedica Medicare Plan members may receive their vaccines from a non-
participating provider.
COVERAGE CRITERIA
HMO, PPO, Individual Marketplace, Elite/ProMedica Medicare Plan, Advantage
Paramount covers certain services under the Preventive Care Services benefit. The standard influenza and
pneumococcal vaccines are provided to all members without a co-pay. Paramount members may receive influenza
and pneumococcal vaccines from any provider that participates with Paramount and who provides influenza and
pneumococcal vaccines as covered in full.
Covered Flu & Pneumonia Codes by Product Line
The following codes are covered without a copay when:
PRODUCT Provided as the ONLY service or with only a
preventive service.
Administered in the office of a participating PCP or
Specialist, or at a participating pharmacy location.
90460, 90461, 90471, 90472, 90473, 90474, 90630, 90653,
HMO, PPO, Individual 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662,
Marketplace 90670, 90672, 90673, 90674, 90677, 90682, 90685, 90686,
90687, 90688, 90689, 90694, 90732, 90756
G0008, G0009, Q2034, Q2035, Q2036, Q2037, Q2038,
Q2039, 90460, 90461, 90473, 90474, 90630, 90653, 90654,
90655, 90656, 90657, 90658, 90660, 90661, 90662, 90670,
90671, 90672, 90673, 90674, 90677, 90682, 90685, 90686,
90687, 90688, 90689, 90694, 90732, 90756
90460, 90471, 90472, 90473, 90474, 90630, 90653, 90654,
90656, 90658, 90660, 90662, 90670, 90672, 90673, 90674,
90682, 90685, 90686, 90687, 90688, 90694, 90732, 90756,
Q2034, Q2035, Q2039
(Advantage administration codes are listed for billing/reporting
purposes only and do not imply payment.)
Routine immunizations with a U.S. Food and Drug Administration (FDA) licensed vaccine are covered as medically
necessary when used in accordance with a recommendation by the Centers for Disease Control and Prevention’s
(CDC) Advisory Committee on Immunization Practices (ACIP).
Coverage criteria are adjusted when national guidelines are revised to address new vaccines or changes in
PG0196 – 10/01/2021vaccine indications, or when the CDC makes recommendations for changes in administration schedules related to
national vaccine shortages.
Influenza and Pneumonia Immunizations are a covered preventive benefit, both for adults and for children
Influenza Vaccination
Standard or preservative-free trivalent or quadrivalent injectable influenza vaccines are considered
medically necessary according to the recommendations of the Centers for Disease Control and
Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
Routine annual influenza vaccination is recommended for all persons aged 6 months and older who do not
have contraindications.
Routine annual influenza vaccination is recommended for health care personnel, caregivers and persons
who live with those who are at increased risk for medical complications attributed to severe influenza.
Vaccination to prevent influenza is particularly important for persons who are at increased risk for severe
illness and complications from influenza and for influenza-related outpatient, emergency department, or
hospital visits.
o All children aged 6 through 59 months;
o All persons aged 50 years and older;
o Adults and children who have chronic pulmonary (including asthma), cardiovascular (excluding
isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including
diabetes mellitus);
o Persons who are immunocompromised due to any cause (including but not limited to
immunosuppression caused by medications or HIV infection);
o Women who are or will be pregnant during the influenza season;
o Children and adolescents (aged 6 months through 18 years) who are receiving aspirin- or salicylate-
containing medications and who might be at risk for experiencing Reye syndrome after influenza
virus infection;
o Residents of nursing homes and other long-term care facilities;
o American Indians/Alaska Natives; and
o Persons who are extremely obese (body mass index ≥40 for adults).
90660 and 90672 (Intranasal flu vaccinations) are covered for aged 2 through 49 years of age if a flu shot is
not the preferred option.
90662, high dose flu vaccine (Fluzone) is covered for members 65 and over only.
Pneumococcal Vaccination
Pneumococcal vaccines are considered medically necessary according to the recommendations of the Centers for
Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13®)
23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23)
13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13) or 23-valent pneumococcal
polysaccharide vaccine (PPSV23) is considered medically necessary and, therefore, covered for the following
individuals:
Children
Routine childhood PCV13 vaccination at ages 2 months, 4 months, 6 months, and 12 months through 15
months. The first dose of PCV13 is covered as early as 6 weeks of age.
Catch-up PCV13 vaccination for under-vaccinated healthy children up to 5 years of age at subsequent
visits.
Adults
PG0196 – 10/01/2021 Standard 23-valent pneumococcal polysaccharide vaccine (PPV23, e.g., Pneumovax, Pnu-immune) is
considered medically necessary for all individuals aged 65 years or older.
Vaccination considered covered for members with high-risk conditions with PCV13 and PPSV23:
Children
o For children 2 years through 18 years of age with any of the following conditions: chronic heart
disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease
(including asthma if treated with high-dose corticosteroid therapy); diabetes mellitus; cerebrospinal
fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional
asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with
immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias,
lymphomas, and Hodgkin disease; solid organ transplantation; acquired or congenital
immunodeficiency; multiple myeloma.
o For children aged 6 through 18 years with alcoholism or chronic liver disease.
Adults
o Adults aged 19 or older with immunocompromising conditions, (e.g., congenital or acquired
immunodeficiency disorders [including B- and T-lymphocyte deficiency, complement deficiencies,
phagocytic disorders], HIV infection, anatomical or functional asplenia [including sickle cell disease
and other hemoglobinopathies], chronic renal failure, leukemia, lymphoma, Hodgkin disease,
generalized malignancy, iatrogenic immunosuppression [e.g. drug or radiation therapy], solid organ
transplant, multiple myeloma, and nephrotic syndrome), cerebrospinal fluid leak, or cochlear implant.
o Adults aged 19 years through 64 years with chronic medical conditions (e.g. chronic heart disease
(excluding hypertension), chronic lung disease, chronic liver disease, diabetes mellitus), alcoholism,
or who smokes cigarettes.
PCV13 and PPSV23, when indicated, will be covered for members whose pneumococcal vaccination
history is incomplete or unknown.
Adults 65 years or older who have not previously received the PCV13 vaccine when indicated by shared
clinical decision-making.
If PPSV23 was administered prior to age 65 years, adults 65 years or older for a routine dose of PPSV23 at
least 5 years after the previous PPSV23 dose.
After heptavalent pneumococcal conjugate vaccine (PCV7) in Alaska Native or American Indian children
aged 24 through 59 months who are living in areas where the risk of invasive pneumococcal disease is
increased.
Alaska Native and American Indian persons aged 50 to 64 years who are living in areas where the risk of
invasive pneumococcal disease is increased, when recommended by public health authorities
Routine re-vaccination is not recommended by the CDC for pneumococcal vaccines.
In accordance with the CDC’s recommendations, re-vaccination is considered medically necessary only for the
following groups:
Persons aged 65 years or older if they received vaccine 5 or more years previously and was less than 65
years of age at the time of vaccination;
Persons aged 2 to 64 years with the following conditions in which the second dose of PPSV23 is given at
least 5 years after the first dose of PPSV23:
o Anatomic or functional asplenia;
o Chronic renal failure or nephrotic syndrome;
o Congenital or acquired immunodeficiency (including HIV infection);
o Generalized and metastatic malignancies;
o Hodgkin disease;
o Iatrogenic immunosuppression, including radiation therapy;
PG0196 – 10/01/2021o Leukemia or lymphoma;
o Multiple myeloma;
o Sickle cell disease or other hemoglobinopathies;
o Solid organ transplant;
o Sickle cell disease or other hemoglobinopathies.
In addition, re-vaccination with the 23-valent pneumococcal polysaccharide vaccine is considered medically
necessary for high-risk individuals who received the 14-valent polysaccharide vaccine, which was in use prior to
1983.
Pneumococcal 13-valent Conjugate Vaccine (PCV13, Prevnar 13)
Note: In 2010, heptavalent pneumococcal conjugate vaccine (PCV7, e.g., Prevnar, Prevenar) was replaced
by PCV13 (e.g., Prevnar 13).
The use of 13-valent pneumococcal conjugate vaccine (PCV 13; Prevnar 13 is considered in series with
PPSV23 (e.g. Pneumovax) medically necessary for adults aged 19 years or older (including those aged 65
years and older) with immunocompromising conditions, CSF leaks, or cochlear implants.
The use of a dose of PCV13 (e.g., Prevnar 13) is considered followed by a dose of PPSV23 (e.g.,
Pneumovax) medically necessary for adults aged 65 years and older who want to receive PCV13 and do
not have an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant and have not
previously received PCV13.
Note: if member already received PPSV23, a dose of PCV13 may be given at least one year after they
received the most recent dose.
Pneumococcal 13-valent conjugate vaccine (PCV13) is considered experimental and investigational for
other groups because its effectiveness for groups other than the ones listed above has not been
established.
CDC recommends some adults receive up to 3 doses of PPSV23 in a lifetime. Adults who have functional or
anatomic asplenia or immunocompromising conditions should receive two doses of PPSV23, given 5 years apart,
before age 65 years. Those adults should then receive a third dose of PPSV23 at or after 65 years, as long as it
has been at least 5 years since the most recent dose.
CDC recommends all adults receive 1 dose of PCV13, if indicated and if they have not received PCV13 previously
(including childhood series). For most people, this will be as part of the routine recommendation to administer
PCV13 to all adults 65 years of age or older. However, if an adult received a dose of PCV13 prior to turning 65
years of age (due to a medical indication), they do not also need to receive a dose of PCV13 when they turn 65.
Note
Codes may not be all inclusive as the American Medical Association (AMA) and Centers for Medicare and
Medicaid Services (CMS) code updates and FDA approvals may occur more frequently than policy updates.
Vaccines and immunizations for the sole purpose of travel outside of the continental United States are not
covered.
Paramount does not reimburse for vaccines that are available free from the state.
Paramount does not reimburse for vaccines that are not FDA-approved
Definitions
Immunity – is protection from an infectious disease
Immunization – is an inoculation against a vaccine preventable disease
Vaccination – the act of introducing a vaccine into the body to produce immunity to a specific disease
PG0196 – 10/01/2021 Vaccine – a preparation of a weakened or dead pathogen that stimulates a person’s immune system to
produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually
administered through needle injections, but can also be administered by mouth or sprayed into the nose
CODING/BILLING INFORMATION
The inclusion or exclusion of a code in this section does not necessarily indicate coverage. Codes referenced in
this clinical policy are for informational purposes only.
Codes that are covered may have selection criteria that must be met.
Payment for supplies may be included in payment for other services rendered.
CPT CODES BRAND NAME
90460 Immunization administration through 18 years of age via any route of
administration, with counseling by physician or other qualified health
care professional; first or only component of each vaccine or toxoid
administered
90461 Immunization administration through 18 years of age via any route of
administration, with counseling by physician or other qualified health
care professional; each additional vaccine or toxoid administered (List
separately in addition to code for primary procedure.)
90471 Immunization administration, one vaccine
90472 Immunization administration, each additional vaccine
90473 Immunization administration by intranasal or oral route; one vaccine
90474 Immunization administration by intranasal or oral route; each additional
vaccine
90630 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, Fluzone Quad Intradermal
for intradermal use
90653 Influenza virus vaccine, inactivated (IIV), subunit, adjuvant, for Fluad
intramuscular use
90654 Influenza virus vaccine, split virus, preservative free, for intradermal use Fluzone
90655 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 Afluria
mL dosage, for intramuscular use
90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 Afluria, Fluvirin, Fluarix
mL dosage, for intramuscular use
90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for Afluria, Flulaval, Fluvirin
intramuscular use
90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for Afluria, FluLaval, Fluvirin
intramuscular use
90660 Influenza virus vaccine, trivalent, live, for intranasal use FluMist
90661 Influenza virus vaccine trivalent (ccIIV3), derived from cell cultures, Flucelvax
subunit, preservative and antibiotic free, 0.5 mL dosage, for
intramuscular use
90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced Fluzone High-Dose
immunogenicity via increased antigen content, for intramuscular
90664 Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal Novel influenza – H1N1-09
use nasal
90670 Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular Prevnar 13
use
90671 Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular Vaxneuvance
use (Effective 7/1/2021)
90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use FluMist
90673 Influenza virus vaccine, trivalent, derived from recombinant DNA (RIV3), Flublok
hemagglutin (HA) protein only, preservative and antibiotic free, for
intramuscular use
90674 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, Flucelvax
subunit, preservative and antibiotic free, 0.5 mL dosage, for
PG0196 – 10/01/2021intramuscular use (Effective 07/01/2016)
90677 Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular Prevnar 20
use (Effective 7/1/2021)
90682 Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant Flublok
DNA, hemagglutinin (HA) protein only, preservative and antibiotic free,
for intramuscular use
90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, Fluzone
0.25 mL dosage, for intramuscular use
90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, Afluria, Fluarix, Fluzone,
0.5 mL dosage, for intramuscular use Flulaval
90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, Fluzone
for intramuscular use
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, Afluria, FluLaval, Fluzone
for intramuscular use
90689 Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted,
preservative free, 0.25 mL dosage, for intramuscular use (Effective
01/01/19)
90694 Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, Fluad Quadrivalent
preservative free, 0.5 mL dosage, for intramuscular use
90732 Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or Pneumovax 23
immunosuppressed patient dosage, when administered to individuals 2
years or older, for subcutaneous or intramuscular use
90756 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, Flucelvax
subunit, antibiotic free, 0.5mL dosage, for intramuscular use
HCPCS CODES
G0008 Administration of influenza virus vaccine
G0009 Administration of pneumococcal vaccine
Q2034 Influenza virus vaccine, split virus, for intramuscular use (Agriflu) Agriflu
Q2035 Influenza virus vaccine, split virus, when administered to individual 3 Afluria
years of age and older, for intramuscular use (Afluria)
Q2036 Influenza virus vaccine, split virus, when administered to individuals 3 Flulaval
years of age and older, for intramuscular use (Flulaval)
Q2037 Influenza virus vaccine, split virus, when administered to individuals 3 Fluvirin
years of age and older, for intramuscular use (Fluvirin)
Q2038 Influenza virus vaccine, split virus, when administered to individuals 3 Fluzone
years of age and older, for intramuscular use (Fluzone)
Q2039 Influenza virus vaccine, split virus, when administered to individuals 3
years of age and older, for intramuscular use (not otherwise specified)
Vaccination Products Pending FDA Approval - Non-Reimbursable CPT
Codes
90666 Influenza virus vaccine (IIV), pandemic formulation, split virus,
preservative free, for intramuscular use
90667 Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvant,
for intramuscular use
90668 Influenza virus vaccine (IIV), pandemic formulation, split virus, for
intramuscular use
Paramount reserves the right to review and revise our policies periodically when necessary. When
there is an update, we will publish the most current policy to
https://www.paramounthealthcare.com/services/providers/medical-policies/ .
REVISION HISTORY EXPLANATION
PG0196 – 10/01/2021ORIGINAL EFFECTIVE DATE: 01/15/2009
Date Explanation & Changes
09/01/09 Updated to include H1N1 vaccine
07/01/10 New vaccines
01/01/11 New codes
01/01/12 Procedure code 90663 was deleted. Procedure code 90654 was added
01/01/13 Procedure codes 90672, 90685, 90686, 90687, 90688, Q2034 were added
Procedure code 90686 received FDA approval 12/12. Removed from Exception.
06/13/13
Medical Policy Reimbursement Committee reviewed 6/13
Added procedure codes 90673 & Q2033 as FDA approved 1/16/13. (Note procedure code
90661 FDA approved 11/12)
08/07/13
Separated codes in the FDA pending state, 90653, 90666, 90667, 90668, 90687, 90688
Policy reviewed and updated to reflect most current clinical evidence
Added Advantage vaccine administration denial
10/08/13
Approved by Medical Policy Steering Committee as revised
03/26/15 Codes 90687 & 90688 now FDA approved
Added codes G0008 & G0009
Added effective 1/1/15 new FDA approved code 90630 as covered
07/14/15 Removed effective 12/31/13 deleted code Q2033
Policy reviewed and updated to reflect most current clinical evidence per Medical Policy
Steering Committee
Per the Medicare Tactical Team’s review and determination, procedures G0008 and G0009
03/25/16 are now non-covered for HMO and PPO and procedures 90471 and 90472 are now non-
covered for Elite
Code 90460 is covered for Advantage now per ODM Appendix DD
05/10/16 Policy reviewed and updated to reflect most current clinical evidence per Medical Policy
Steering Committee
Added effective 7/1/16 new code 90674 as covered for all product lines per administrative
10/13/16
direction
Updated effective 1/1/17 revised codes 90655-90658, 90661, 90685-90688
Added effective 1/1/17 new code 90682 as pending FDA approval non-covered
11/08/16 Code 90653 now FDA approved and covered for all product lines
Policy reviewed and updated to reflect most current clinical evidence per Medical Policy
Steering Committee
Code 90682 is now FDA approved and covered for all product lines
Added effective 01/01/18 new code 90756 as covered for all product lines
01/09/18
Policy reviewed and updated to reflect most current clinical evidence per Medical Policy
Steering Committee
Fluzone high-dose (90662) vaccine is now covered for Advantage effective 11/01/2018 per
ODM guidelines
Added effective 01/01/19 new code 90689 as covered for all product lines
Code 90664 (pandemic vaccine) is non-covered for HMO, PPO, Individual Marketplace, &
11/13/18:
Elite
Removed effective 12/31/15 deleted code 90669
Policy reviewed and updated to reflect most current clinical evidence per Medical Policy
Steering Committee
New code 90689 effective 01/01/19 is non-covered for Advantage per ODM guidelines
01/08/19 Policy reviewed and updated to reflect most current clinical evidence per Medical Policy
Steering Committee
Added procedure code 90694 to the medical policy coverage Elite and Commercial product
8/4/2020 lines
Note: procedure 90694 is listed on the medical policy PG0137 Preventive Services
12/16/2020 Medical policy placed on the new Paramount Medical Policy Format
PG0196 – 10/01/2021 Added procedures 90662 (10/01/2020), 90694 (01/01/2021), Q2034 (07/01/2012), Q2035
(01/01/2020), Q2039 (08/01/2017) to the Advantage coverage per ODM List of vaccines,
toxoids, and other provider-administered injectable pharmaceuticals provided as
practitioner services and referenced in rule 5160-4-12, revised 3/18/2021
05/04/2021 Deleted procedures 90655 (04/01/2007), 90657 (07/01/2008), 90664 (01/01/2011), to the
Advantage coverage per ODM List of vaccines, toxoids, and other provider-administered
injectable pharmaceuticals provided as practitioner services and referenced in rule 5160-4-
12, revised 3/18/2021
Added procedure 90658 to the Elite coverage - covered as a Part B benefit
Policy reviewed and updated to reflect most current clinical evidence per Industry
Standards
10/01/2021
Added procedure codes 90671 and 90677 to the Elite/ProMedica Medicare Plan and HMO,
PPO, Individual Marketplace product lines, effective 7/1/2021
REFERENCES/RESOURCES
Centers for Medicare and Medicaid Services, CMS Manual System and other CMS publications and
services
Ohio Department of Medicaid
American Medical Association, Current Procedural Terminology (CPT®) and associated publications and
services
Centers for Medicare and Medicaid Services, Healthcare Common Procedure Coding System, HCPCS
Release and Code Sets
U.S. Preventive Services Task Force, http://www.uspreventiveservicestaskforce.org/
Industry Standard Review
Hayes, Inc.
Industry Standard Review
CDC http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/index.html
PG0196 – 10/01/2021You can also read
